Guidelines for parenteral fluid management for terminal cancer patients

Takashi Higashiguchi, Junichi Ikegaki, Kazuya Sobue, Yoichiro Tamura, Nobuhisa Nakajima, Akihiko Futamura, Mitsunori Miyashita, Naoharu Mori, Akio Inui, Keiichiro Ohta, Toyoshi Hosokawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Japan's first guidelines for parenteral fluid management for terminal cancer patients were issued in 2006. These guidelines focused on the fluid levels to administer to patients with a remaining life expectancy of 1-2 months. However, recent refinement of the concept of cachexia is prompting caregivers worldwide to rethink parenteral fluid management for terminal cancer patients. Objective: Our objective was to develop guidelines for parenteral fluid management for terminal cancer patients with a remaining life expectancy of 1 month, a point when cachexia generally begins to severely adversely affect the body. Methods: The Japanese Society for Palliative Medicine appointed a Guidelines Working Practitioner Group consisting of a multidisciplinary team of specialists. In response to 26 clinical questions on parenteral fluid management for terminal cancer patients, the Working Group used the Delphi method to reach consensus on the recommendability and evidence level of 89 relevant manuscripts identified through a systematic literature review. The Working Group then had an outside committee reviews the draft guidelines validity before authoring the final version. Results: The resulting clinically aligned guidelines contain specific recommendations (25 recommendations on physical suffering/remaining life expectancy, 10 nursing-related recommendations and 4 ethical recommendations) assessed using the Delphi method and by an outside committee. Conclusions: Japanese Society for Palliative Medicine released a revised edition of the Guidelines for Parenteral Fluid Management for Terminal Cancer Patients, which are based on medical evidence and consider the pathologic features of cachexia. We recommend that caregivers carefully evaluate the clinical usefulness of the guidelines.

Original languageEnglish
Pages (from-to)986-992
Number of pages7
JournalJapanese journal of clinical oncology
Volume46
Issue number11
DOIs
Publication statusPublished - 01-01-2016

Fingerprint

Guidelines
Cachexia
Neoplasms
Life Expectancy
Caregivers
Manuscripts
Advisory Committees
Consensus
Japan
Nursing
Pain
Palliative Medicine

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Higashiguchi, T., Ikegaki, J., Sobue, K., Tamura, Y., Nakajima, N., Futamura, A., ... Hosokawa, T. (2016). Guidelines for parenteral fluid management for terminal cancer patients. Japanese journal of clinical oncology, 46(11), 986-992. https://doi.org/10.1093/jjco/hyw105
Higashiguchi, Takashi ; Ikegaki, Junichi ; Sobue, Kazuya ; Tamura, Yoichiro ; Nakajima, Nobuhisa ; Futamura, Akihiko ; Miyashita, Mitsunori ; Mori, Naoharu ; Inui, Akio ; Ohta, Keiichiro ; Hosokawa, Toyoshi. / Guidelines for parenteral fluid management for terminal cancer patients. In: Japanese journal of clinical oncology. 2016 ; Vol. 46, No. 11. pp. 986-992.
@article{d5912320aa524d71b370f09bdac3727c,
title = "Guidelines for parenteral fluid management for terminal cancer patients",
abstract = "Background: Japan's first guidelines for parenteral fluid management for terminal cancer patients were issued in 2006. These guidelines focused on the fluid levels to administer to patients with a remaining life expectancy of 1-2 months. However, recent refinement of the concept of cachexia is prompting caregivers worldwide to rethink parenteral fluid management for terminal cancer patients. Objective: Our objective was to develop guidelines for parenteral fluid management for terminal cancer patients with a remaining life expectancy of 1 month, a point when cachexia generally begins to severely adversely affect the body. Methods: The Japanese Society for Palliative Medicine appointed a Guidelines Working Practitioner Group consisting of a multidisciplinary team of specialists. In response to 26 clinical questions on parenteral fluid management for terminal cancer patients, the Working Group used the Delphi method to reach consensus on the recommendability and evidence level of 89 relevant manuscripts identified through a systematic literature review. The Working Group then had an outside committee reviews the draft guidelines validity before authoring the final version. Results: The resulting clinically aligned guidelines contain specific recommendations (25 recommendations on physical suffering/remaining life expectancy, 10 nursing-related recommendations and 4 ethical recommendations) assessed using the Delphi method and by an outside committee. Conclusions: Japanese Society for Palliative Medicine released a revised edition of the Guidelines for Parenteral Fluid Management for Terminal Cancer Patients, which are based on medical evidence and consider the pathologic features of cachexia. We recommend that caregivers carefully evaluate the clinical usefulness of the guidelines.",
author = "Takashi Higashiguchi and Junichi Ikegaki and Kazuya Sobue and Yoichiro Tamura and Nobuhisa Nakajima and Akihiko Futamura and Mitsunori Miyashita and Naoharu Mori and Akio Inui and Keiichiro Ohta and Toyoshi Hosokawa",
year = "2016",
month = "1",
day = "1",
doi = "10.1093/jjco/hyw105",
language = "English",
volume = "46",
pages = "986--992",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "11",

}

Higashiguchi, T, Ikegaki, J, Sobue, K, Tamura, Y, Nakajima, N, Futamura, A, Miyashita, M, Mori, N, Inui, A, Ohta, K & Hosokawa, T 2016, 'Guidelines for parenteral fluid management for terminal cancer patients', Japanese journal of clinical oncology, vol. 46, no. 11, pp. 986-992. https://doi.org/10.1093/jjco/hyw105

Guidelines for parenteral fluid management for terminal cancer patients. / Higashiguchi, Takashi; Ikegaki, Junichi; Sobue, Kazuya; Tamura, Yoichiro; Nakajima, Nobuhisa; Futamura, Akihiko; Miyashita, Mitsunori; Mori, Naoharu; Inui, Akio; Ohta, Keiichiro; Hosokawa, Toyoshi.

In: Japanese journal of clinical oncology, Vol. 46, No. 11, 01.01.2016, p. 986-992.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Guidelines for parenteral fluid management for terminal cancer patients

AU - Higashiguchi, Takashi

AU - Ikegaki, Junichi

AU - Sobue, Kazuya

AU - Tamura, Yoichiro

AU - Nakajima, Nobuhisa

AU - Futamura, Akihiko

AU - Miyashita, Mitsunori

AU - Mori, Naoharu

AU - Inui, Akio

AU - Ohta, Keiichiro

AU - Hosokawa, Toyoshi

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background: Japan's first guidelines for parenteral fluid management for terminal cancer patients were issued in 2006. These guidelines focused on the fluid levels to administer to patients with a remaining life expectancy of 1-2 months. However, recent refinement of the concept of cachexia is prompting caregivers worldwide to rethink parenteral fluid management for terminal cancer patients. Objective: Our objective was to develop guidelines for parenteral fluid management for terminal cancer patients with a remaining life expectancy of 1 month, a point when cachexia generally begins to severely adversely affect the body. Methods: The Japanese Society for Palliative Medicine appointed a Guidelines Working Practitioner Group consisting of a multidisciplinary team of specialists. In response to 26 clinical questions on parenteral fluid management for terminal cancer patients, the Working Group used the Delphi method to reach consensus on the recommendability and evidence level of 89 relevant manuscripts identified through a systematic literature review. The Working Group then had an outside committee reviews the draft guidelines validity before authoring the final version. Results: The resulting clinically aligned guidelines contain specific recommendations (25 recommendations on physical suffering/remaining life expectancy, 10 nursing-related recommendations and 4 ethical recommendations) assessed using the Delphi method and by an outside committee. Conclusions: Japanese Society for Palliative Medicine released a revised edition of the Guidelines for Parenteral Fluid Management for Terminal Cancer Patients, which are based on medical evidence and consider the pathologic features of cachexia. We recommend that caregivers carefully evaluate the clinical usefulness of the guidelines.

AB - Background: Japan's first guidelines for parenteral fluid management for terminal cancer patients were issued in 2006. These guidelines focused on the fluid levels to administer to patients with a remaining life expectancy of 1-2 months. However, recent refinement of the concept of cachexia is prompting caregivers worldwide to rethink parenteral fluid management for terminal cancer patients. Objective: Our objective was to develop guidelines for parenteral fluid management for terminal cancer patients with a remaining life expectancy of 1 month, a point when cachexia generally begins to severely adversely affect the body. Methods: The Japanese Society for Palliative Medicine appointed a Guidelines Working Practitioner Group consisting of a multidisciplinary team of specialists. In response to 26 clinical questions on parenteral fluid management for terminal cancer patients, the Working Group used the Delphi method to reach consensus on the recommendability and evidence level of 89 relevant manuscripts identified through a systematic literature review. The Working Group then had an outside committee reviews the draft guidelines validity before authoring the final version. Results: The resulting clinically aligned guidelines contain specific recommendations (25 recommendations on physical suffering/remaining life expectancy, 10 nursing-related recommendations and 4 ethical recommendations) assessed using the Delphi method and by an outside committee. Conclusions: Japanese Society for Palliative Medicine released a revised edition of the Guidelines for Parenteral Fluid Management for Terminal Cancer Patients, which are based on medical evidence and consider the pathologic features of cachexia. We recommend that caregivers carefully evaluate the clinical usefulness of the guidelines.

UR - http://www.scopus.com/inward/record.url?scp=85014350054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014350054&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyw105

DO - 10.1093/jjco/hyw105

M3 - Article

AN - SCOPUS:85014350054

VL - 46

SP - 986

EP - 992

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 11

ER -